EUVIMEDEUVIMED entdecken
Crossref

Contribution of APOE Genetic Variants to Dyslipidemia

Ana M Bea iD, Asier Larrea-Sebal, Victoria Marco-Benedi iD, Kepa B Uribe, Unai Galicia-Garcia, Itziar Lamiquiz-Moneo, Martín Laclaustra, Belén Moreno-Franco, Pablo Fernandez-Corredoira, Salvador Olmos, Fernando Civeira iD, César Martin iD und 1 weitere

Arteriosclerosis, Thrombosis, and Vascular Biology · 2023

DOI: 10.1161/atvbaha.123.318977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023. Verfasst von Ana M Bea und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Spain (A.M.B., V.M.-B., I.L.-M., M.L., P.F.-C., F.C., A.C.). Hauptthemen laut MEDLINE: Hypercholesterolemia, Hyperlipidemias, Hyperlipoproteinemia Type III. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: apo (apolipoprotein) E has crucial role in lipid metabolism. The genetic variation in APOE gene is associated with monogenic disorders and contributes to polygenic hypercholesterolemia and to interindividual variability in cholesterol. APOE rare variants may be involved in the phenotype of genetic hyperlipidemias.

Methods

Exon 4 of APOE were sequenced in all consecutive unrelated subjects with primary hyperlipidemia from a Lipid Unit (n=3667) and 822 random subjects from the Aragon Workers Health Study. Binding affinity of VLDL (very low-density lipoprotein) to LDL receptor of pathogenic predicted apoE variants was analyzed in vitro. Lipoprotein particle number, size, and composition were studied by nuclear magnetic resonance.

Results

In addition to common polymorphisms giving rise to APOE2 and APOE4, 14 gene variants were found in exon 4 of APOE in 65 subjects. p.(Leu167del) in 8 patients with isolated hypercholesterolemia and in 8 patients with combined hyperlipidemia. Subjects with p.(Arg121Trp), p.(Gly145Asp), p.(Arg154Ser), p.(Arg163Cys), p.(Arg165Trp), and p.(Arg168His) variants met dysbetalipoproteinemia lipid criteria and were confirmed by nuclear magnetic resonance. VLDL affinity for the LDL receptor of p.(Arg163Cys) and p.(Arg165Trp) heterozygous carriers had intermedium affinity between APOE2/2 and APOE3/3. p.(Gly145Asp) and p.(Pro220Leu) variants had higher affinity than APOE3/3.

Conclusions

APOE genetic variation contributes to the development of combined hyperlipidemia, usually dysbetalipoproteinemia, and familial hypercholesterolemia. The lipid phenotype in heterozygous for dysbetalipoproteinemia-associated mutations is milder than the homozygous APOE2/2-associated phenotype. Subjects with dysbetalipoproteinemia and absence of APOE2/2 are good candidates for the study of pathogenic variants in APOE . However, more investigation is required to elucidate the significance of rarer variants of apoE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercholesterolemiaHyperlipidemiasHyperlipoproteinemia Type IIIHumansApolipoprotein E2Apolipoprotein E3Apolipoproteins EReceptors, LDL

Stichwörter der Autor:innen

apolipoproteinexonlipid metabolismmutationphenotype

Substanzen

Apolipoprotein E2Apolipoprotein E3Apolipoproteins EReceptors, LDLApoE protein, human

Autor:innen und Institutionen

  • Hospital Universitario Miguel Servet, IIS Aragón, CIBERCV, Spain (A.M.B., V.M.-B., I.L.-M., M.L., P.F.-C., F.C., A.C.).
  • Biofisika Institute (UPV/EHU, CSIC), University of the Basque Country, Leioa, Spain (A.L.-S., C.M.).
  • Fundación Biofísica Bizkaia, Leioa, Spain (A.L.-S.).
  • Universidad de Zaragoza, Spain (V.M.-B., I.L.-M., M.L., B.M.-F., S.O., F.C.).
  • Department of Biochemistry and Molecular Biology, UPV/EHU, University of the Basque Country, Bilbao, Spain (K.B.U., U.G.-G., C.M.).
  • Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Spain (K.B.U.).

ORCID-Profile: Ana M Bea, Victoria Marco-Benedi, Fernando Civeira, César Martin

Zitieren

APA

Bea, A. M., Larrea-Sebal, A., Marco-Benedi, V., Uribe, K. B., Galicia-Garcia, U., Lamiquiz-Moneo, I., Laclaustra, M., Moreno-Franco, B., Fernandez-Corredoira, P., Olmos, S., Civeira, F., Martin, C., & Cenarro, A. (2023). Contribution of APOE Genetic Variants to Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.123.318977

Vancouver

Bea AM, Larrea-Sebal A, Marco-Benedi V, Uribe KB, Galicia-Garcia U, Lamiquiz-Moneo I, et al. Contribution of APOE Genetic Variants to Dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023. doi:10.1161/atvbaha.123.318977

BibTeX
@article{Bea2023,
  author = {Bea, Ana M and Larrea-Sebal, Asier and Marco-Benedi, Victoria and Uribe, Kepa B and Galicia-Garcia, Unai and Lamiquiz-Moneo, Itziar and Laclaustra, Martín and Moreno-Franco, Belén and Fernandez-Corredoira, Pablo and Olmos, Salvador and Civeira, Fernando and Martin, César and Cenarro, Ana},
  title = {Contribution of APOE Genetic Variants to Dyslipidemia},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2023},
  doi = {10.1161/atvbaha.123.318977}
}
Kostenlos starten →